New drug ST-001 tested in lung cancer patients who have run out of options
NCT ID NCT06922539
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 17 times
Summary
This early-phase trial is testing a new drug called ST-001 in people with small cell lung cancer that has returned or stopped responding to standard treatments. The main goal is to find the safest dose and check for side effects. About 44 participants will receive the drug through an IV for five days every three weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Southern California
RECRUITINGLos Angles, California, 90007, United States
Conditions
Explore the condition pages connected to this study.